Dainippon Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Teruko Ariyama

Takashi Nakagawa

Yasushi Ochiai

Mayumi Nakamura

Hirohisa Kobayashi

Kazuya Otoda

A tablet containing droxidopa as an active ingredient in a proportion of 20-80 wt % relative to the total weight of the tablet, and characteristically containing at least one excipient selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose, and corn-derived starch is provided. In addition, a preparation containing corn-derived processed starch or polyvinyl alcohol as a binder and the like, which is a stable tablet containing droxidopa as an active ingredient, is provided.

Stable tablet containing droxidopa

A solution-type preparation of lurasidone comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2&#x2032;S,3&#x2032;R,4&#x2032;S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) as an active ingredient and containing at least one substance selected from benzyl alcohol, N,N-dimethylacetamide, lactic acid and propylene glycol.

Solubilization preparation

Growing community of inventors

Ibaraki, Japan

Teruko Ariyama